COFCO Biotechnology Balance Sheet Health
Financial Health criteria checks 6/6
COFCO Biotechnology has a total shareholder equity of CN¥10.8B and total debt of CN¥5.1B, which brings its debt-to-equity ratio to 46.7%. Its total assets and total liabilities are CN¥18.4B and CN¥7.6B respectively. COFCO Biotechnology's EBIT is CN¥73.9M making its interest coverage ratio -48.9. It has cash and short-term investments of CN¥1.7B.
Key information
46.7%
Debt to equity ratio
CN¥5.07b
Debt
| Interest coverage ratio | -48.9x |
| Cash | CN¥1.68b |
| Equity | CN¥10.85b |
| Total liabilities | CN¥7.60b |
| Total assets | CN¥18.45b |
Recent financial health updates
Recent updates
COFCO Biotechnology Co., Ltd. (SZSE:000930) Looks Inexpensive But Perhaps Not Attractive Enough
Jul 17
COFCO Biotechnology (SZSE:000930) Is Carrying A Fair Bit Of Debt
Jun 03Returns On Capital Signal Tricky Times Ahead For COFCO Biotechnology (SZSE:000930)
Apr 17COFCO Biotechnology Co., Ltd.'s (SZSE:000930) Price Is Right But Growth Is Lacking
Mar 07Financial Position Analysis
Short Term Liabilities: 000930's short term assets (CN¥8.1B) exceed its short term liabilities (CN¥7.0B).
Long Term Liabilities: 000930's short term assets (CN¥8.1B) exceed its long term liabilities (CN¥568.4M).
Debt to Equity History and Analysis
Debt Level: 000930's net debt to equity ratio (31.2%) is considered satisfactory.
Reducing Debt: 000930's debt to equity ratio has reduced from 64.1% to 46.7% over the past 5 years.
Debt Coverage: 000930's debt is well covered by operating cash flow (40.5%).
Interest Coverage: 000930 earns more interest than it pays, so coverage of interest payments is not a concern.